239 related articles for article (PubMed ID: 34030643)
1. Efficacy and safety of rucaparib in previously treated, locally advanced or metastatic urothelial carcinoma from a phase 2, open-label trial (ATLAS).
Grivas P; Loriot Y; Morales-Barrera R; Teo MY; Zakharia Y; Feyerabend S; Vogelzang NJ; Grande E; Adra N; Alva A; Necchi A; Rodriguez-Vida A; Gupta S; Josephs DH; Srinivas S; Wride K; Thomas D; Simmons A; Loehr A; Dusek RL; Nepert D; Chowdhury S
BMC Cancer; 2021 May; 21(1):593. PubMed ID: 34030643
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2.
Oza AM; Tinker AV; Oaknin A; Shapira-Frommer R; McNeish IA; Swisher EM; Ray-Coquard I; Bell-McGuinn K; Coleman RL; O'Malley DM; Leary A; Chen LM; Provencher D; Ma L; Brenton JD; Konecny GE; Castro CM; Giordano H; Maloney L; Goble S; Lin KK; Sun J; Raponi M; Rolfe L; Kristeleit RS
Gynecol Oncol; 2017 Nov; 147(2):267-275. PubMed ID: 28882436
[TBL] [Abstract][Full Text] [Related]
3. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.
Swisher EM; Lin KK; Oza AM; Scott CL; Giordano H; Sun J; Konecny GE; Coleman RL; Tinker AV; O'Malley DM; Kristeleit RS; Ma L; Bell-McGuinn KM; Brenton JD; Cragun JM; Oaknin A; Ray-Coquard I; Harrell MI; Mann E; Kaufmann SH; Floquet A; Leary A; Harding TC; Goble S; Maloney L; Isaacson J; Allen AR; Rolfe L; Yelensky R; Raponi M; McNeish IA
Lancet Oncol; 2017 Jan; 18(1):75-87. PubMed ID: 27908594
[TBL] [Abstract][Full Text] [Related]
4. Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial.
Kristeleit R; Lisyanskaya A; Fedenko A; Dvorkin M; de Melo AC; Shparyk Y; Rakhmatullina I; Bondarenko I; Colombo N; Svintsitskiy V; Biela L; Nechaeva M; Lorusso D; Scambia G; Cibula D; Póka R; Oaknin A; Safra T; Mackowiak-Matejczyk B; Ma L; Thomas D; Lin KK; McLachlan K; Goble S; Oza AM
Lancet Oncol; 2022 Apr; 23(4):465-478. PubMed ID: 35298906
[TBL] [Abstract][Full Text] [Related]
5. A Phase I-II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline
Kristeleit R; Shapiro GI; Burris HA; Oza AM; LoRusso P; Patel MR; Domchek SM; Balmaña J; Drew Y; Chen LM; Safra T; Montes A; Giordano H; Maloney L; Goble S; Isaacson J; Xiao J; Borrow J; Rolfe L; Shapira-Frommer R
Clin Cancer Res; 2017 Aug; 23(15):4095-4106. PubMed ID: 28264872
[No Abstract] [Full Text] [Related]
6. Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial.
Ledermann JA; Oza AM; Lorusso D; Aghajanian C; Oaknin A; Dean A; Colombo N; Weberpals JI; Clamp AR; Scambia G; Leary A; Holloway RW; Gancedo MA; Fong PC; Goh JC; O'Malley DM; Armstrong DK; Banerjee S; García-Donas J; Swisher EM; Cameron T; Maloney L; Goble S; Coleman RL
Lancet Oncol; 2020 May; 21(5):710-722. PubMed ID: 32359490
[TBL] [Abstract][Full Text] [Related]
7. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.
Coleman RL; Oza AM; Lorusso D; Aghajanian C; Oaknin A; Dean A; Colombo N; Weberpals JI; Clamp A; Scambia G; Leary A; Holloway RW; Gancedo MA; Fong PC; Goh JC; O'Malley DM; Armstrong DK; Garcia-Donas J; Swisher EM; Floquet A; Konecny GE; McNeish IA; Scott CL; Cameron T; Maloney L; Isaacson J; Goble S; Grace C; Harding TC; Raponi M; Sun J; Lin KK; Giordano H; Ledermann JA;
Lancet; 2017 Oct; 390(10106):1949-1961. PubMed ID: 28916367
[TBL] [Abstract][Full Text] [Related]
8. Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a
Abida W; Patnaik A; Campbell D; Shapiro J; Bryce AH; McDermott R; Sautois B; Vogelzang NJ; Bambury RM; Voog E; Zhang J; Piulats JM; Ryan CJ; Merseburger AS; Daugaard G; Heidenreich A; Fizazi K; Higano CS; Krieger LE; Sternberg CN; Watkins SP; Despain D; Simmons AD; Loehr A; Dowson M; Golsorkhi T; Chowdhury S;
J Clin Oncol; 2020 Nov; 38(32):3763-3772. PubMed ID: 32795228
[TBL] [Abstract][Full Text] [Related]
9. Rucaparib: a novel PARP inhibitor for
Colombo I; Lheureux S; Oza AM
Drug Des Devel Ther; 2018; 12():605-617. PubMed ID: 29606854
[TBL] [Abstract][Full Text] [Related]
10. A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45).
Monk BJ; Parkinson C; Lim MC; O'Malley DM; Oaknin A; Wilson MK; Coleman RL; Lorusso D; Bessette P; Ghamande S; Christopoulou A; Provencher D; Prendergast E; Demirkiran F; Mikheeva O; Yeku O; Chudecka-Glaz A; Schenker M; Littell RD; Safra T; Chou HH; Morgan MA; Drochýtek V; Barlin JN; Van Gorp T; Ueland F; Lindahl G; Anderson C; Collins DC; Moore K; Marme F; Westin SN; McNeish IA; Shih D; Lin KK; Goble S; Hume S; Fujiwara K; Kristeleit RS
J Clin Oncol; 2022 Dec; 40(34):3952-3964. PubMed ID: 35658487
[TBL] [Abstract][Full Text] [Related]
11. A phase 1 study of PARP-inhibitor ABT-767 in advanced solid tumors with BRCA1/2 mutations and high-grade serous ovarian, fallopian tube, or primary peritoneal cancer.
van der Biessen DAJ; Gietema JA; de Jonge MJA; Desar IME; den Hollander MW; Dudley M; Dunbar M; Hetman R; Serpenti C; Xiong H; Mittapalli RK; Timms KM; Ansell P; Ratajczak CK; Shepherd SP; van Herpen CML
Invest New Drugs; 2018 Oct; 36(5):828-835. PubMed ID: 29313279
[TBL] [Abstract][Full Text] [Related]
12. Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer.
Drew Y; Ledermann J; Hall G; Rea D; Glasspool R; Highley M; Jayson G; Sludden J; Murray J; Jamieson D; Halford S; Acton G; Backholer Z; Mangano R; Boddy A; Curtin N; Plummer R
Br J Cancer; 2016 Mar; 114(7):723-30. PubMed ID: 27002934
[TBL] [Abstract][Full Text] [Related]
13. ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA-MONO) and rucaparib in combination with nivolumab (ATHENA-COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer.
Monk BJ; Coleman RL; Fujiwara K; Wilson MK; Oza AM; Oaknin A; O'Malley DM; Lorusso D; Westin SN; Safra T; Herzog TJ; Marmé F; N Eskander R; Lin KK; Shih D; Goble S; Grechko N; Hume S; Maloney L; McNeish IA; Kristeleit RS
Int J Gynecol Cancer; 2021 Dec; 31(12):1589-1594. PubMed ID: 34593565
[TBL] [Abstract][Full Text] [Related]
14. Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial.
Moore KN; Secord AA; Geller MA; Miller DS; Cloven N; Fleming GF; Wahner Hendrickson AE; Azodi M; DiSilvestro P; Oza AM; Cristea M; Berek JS; Chan JK; Rimel BJ; Matei DE; Li Y; Sun K; Luptakova K; Matulonis UA; Monk BJ
Lancet Oncol; 2019 May; 20(5):636-648. PubMed ID: 30948273
[TBL] [Abstract][Full Text] [Related]
15. Characterization of patients with long-term responses to rucaparib treatment in recurrent ovarian cancer.
Swisher EM; Kristeleit RS; Oza AM; Tinker AV; Ray-Coquard I; Oaknin A; Coleman RL; Burris HA; Aghajanian C; O'Malley DM; Leary A; Welch S; Provencher D; Shapiro GI; Chen LM; Shapira-Frommer R; Kaufmann SH; Goble S; Maloney L; Kwan T; Lin KK; McNeish IA
Gynecol Oncol; 2021 Dec; 163(3):490-497. PubMed ID: 34602290
[TBL] [Abstract][Full Text] [Related]
16. Rucaparib: A Poly(ADP-Ribose) Polymerase Inhibitor for BRCA-Mutated Relapsed Ovarian Cancer.
Moore DC; Ringley JT; Patel J
J Pharm Pract; 2019 Apr; 32(2):219-224. PubMed ID: 29166829
[TBL] [Abstract][Full Text] [Related]
17. Olaparib treatment for platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency status: Phase II LIGHT study primary analysis.
Cadoo K; Simpkins F; Mathews C; Liu YL; Provencher D; McCormick C; ElNaggar AC; Altman AD; Gilbert L; Black D; Kabil N; Bennett J; Munley J; Aghajanian C
Gynecol Oncol; 2022 Sep; 166(3):425-431. PubMed ID: 35803835
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study.
Siefker-Radtke AO; Necchi A; Park SH; García-Donas J; Huddart RA; Burgess EF; Fleming MT; Rezazadeh Kalebasty A; Mellado B; Varlamov S; Joshi M; Duran I; Tagawa ST; Zakharia Y; Akapame S; Santiago-Walker AE; Monga M; O'Hagan A; Loriot Y;
Lancet Oncol; 2022 Feb; 23(2):248-258. PubMed ID: 35030333
[TBL] [Abstract][Full Text] [Related]
19. Rucaparib in patients with BAP1-deficient or BRCA1-deficient mesothelioma (MiST1): an open-label, single-arm, phase 2a clinical trial.
Fennell DA; King A; Mohammed S; Branson A; Brookes C; Darlison L; Dawson AG; Gaba A; Hutka M; Morgan B; Nicholson A; Richards C; Wells-Jordan P; Murphy GJ; Thomas A;
Lancet Respir Med; 2021 Jun; 9(6):593-600. PubMed ID: 33515503
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity of the poly(ADP-ribose) polymerase inhibitor rucaparib as monotherapy in patients with platinum-sensitive, relapsed,
Kristeleit RS; Oaknin A; Ray-Coquard I; Leary A; Balmaña J; Drew Y; Oza AM; Shapira-Frommer R; Domchek SM; Cameron T; Maloney L; Goble S; Lorusso D; Ledermann JA; McNeish IA
Int J Gynecol Cancer; 2019 Nov; 29(9):1396-1404. PubMed ID: 31685558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
